がん遺伝子阻害剤の世界市場レポート2025年

がん遺伝子阻害剤市場規模は、今後数年間で力強い成長が見込まれます。2029年には年間平均成長率（CAGR）8.7％で603億6,000万米ドルに成長します。この予測期間における成長は、ヘルスケア投資の増加、腫瘍診断治療の重視、標的治療の使用増加、支持的な規制と償還の枠組み、個別化医療とコンパニオン診断の進展によるものです。この期間に予想される主な動向には、次世代KRAS阻害剤の出現、AIを活用した創薬プラットフォーム、リアルタイム・リキッドバイオプシーの統合、腫瘍微小環境の調節、標的ナノ粒子ベースのドラッグデリバリーシステムの開発などがあります。

がんの有病率の増加は、がん遺伝子阻害剤市場の今後の成長を促進すると予想されます。がんは、体内の異常細胞の制御不能な増殖と拡散を特徴とする疾患群を指します。喫煙、食生活の乱れ、運動不足、飲酒などの生活習慣が体を弱らせ、がん細胞の増殖を促進するため、不健康なライフスタイルが原因で増加しています。がん遺伝子阻害剤は、がん細胞の増殖を促進する特定の遺伝子を標的としブロックすることで、腫瘍の発生や進行を遅らせたり止めたりすることで、がんと闘う助けとなります。例えば、英国を拠点とする慈善団体Cancer Research UKが2024年7月に発表した報告書によると、英国における新規メラノーマ皮膚がん患者の年間平均数は、2023-2025年の約20,800人から2038-2040年には約26,500人に増加すると予想されています。したがって、がんの有病率の増加ががん遺伝子阻害剤市場の成長を牽引しています。

がん遺伝子阻害剤市場で事業を展開する主要企業は、がん治療の精度と有効性を高めるため、新規機能的ゲノムアプローチなどの革新的な治療法の開発に注力しています。新規ファンクショナルゲノムアプローチとは、さまざまなゲノム、トランスクリプトーム、エピゲノムデータを統合し、がんのような疾患における遺伝子機能とその役割を理解する先進的な手法を指します。例えば、2024年5月、米国のバイオテクノロジー企業であるデルフィア・セラピューティクス社は、がん遺伝子の過剰活性化に対するがんの脆弱性を利用する活性化致死と呼ばれる新規アプローチを発表しました。がん治療薬開発の第一人者であるケビン・マークス、ビル・セラーズ、マイク・ディロンは、この戦略を推進するために6,700万米ドルの資金を確保しました。活性化致死は、がん遺伝子の過剰な活性化を標的とします。がん遺伝子は、変異したり高発現したりすると、がんの発生を促進します。がん細胞の中には、この過剰活性化に依存して生存しているものがあり、標的を絞った介入によって致死的ストレスを誘発することで、健康ながん細胞は温存しつつ、そのようながん細胞を選択的に死滅させるアプローチです。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、貿易戦争と関税、そしてコロナ禍と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界のがん遺伝子阻害剤：PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界のがん遺伝子阻害剤市場：成長率分析
• 世界のがん遺伝子阻害剤市場の実績：規模と成長, 2019-2024
• 世界のがん遺伝子阻害剤市場の予測：規模と成長, 2024-2029, 2034F
• 世界のがん遺伝子阻害剤：総潜在市場規模（TAM）

第6章 市場セグメンテーション

• 世界のがん遺伝子阻害剤市場：タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• オーラル
• 注射
• 世界のがん遺伝子阻害剤市場：薬剤クラス別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 低分子医薬品
• 生物学的製剤
• 併用療法
• 世界のがん遺伝子阻害剤市場：適応症別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 乳がん
• 卵巣がん
• 肺がん
• 膵臓がん
• その他の適応症
• 世界のがん遺伝子阻害剤市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院薬局
• 小売薬局
• オンライン薬局
• 世界のがん遺伝子阻害剤市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• 専門クリニック
• その他のエンドユーザー
• 世界のがん遺伝子阻害剤市場、口腔のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 低分子阻害剤
• 標的治療薬
• チロシンキナーゼ阻害剤（TKI）
• 世界のがん遺伝子阻害剤市場、注射のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• モノクローナル抗体（MAbs）
• ペプチド受容体放射性リガンド療法（PRRT）
• 小分子阻害剤（注射剤）
• 遺伝子治療注射

第7章 地域別・国別分析

• 世界のがん遺伝子阻害剤市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界のがん遺伝子阻害剤市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• がん遺伝子阻害剤市場：競合情勢
• がん遺伝子阻害剤市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Johnson & Johnson Services Inc. Overview, Products and Services, Strategy and Financial Analysis
  • F. Hoffmann-La Roche Ltd Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Bayer AG
• Bristol-Myers Squibb Company
• Novartis AG
• GlaxoSmithKline plc
• Takeda Pharmaceutical Company Limited
• Eli Lilly and Company
• Mirati Therapeutics Inc.
• AstraZeneca PLC
• Incyte Corporation
• Blueprint Medicines Corporation
• Astex Pharmaceuticals Inc.
• G1 Therapeutics Inc.
• Nurix Therapeutics Inc.
• GenFleet Therapeutics Co Ltd.
• Relay Therapeutics Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• がん遺伝子阻害剤市場2029：新たな機会を提供する国
• がん遺伝子阻害剤市場2029：新たな機会を提供するセグメント
• がん遺伝子阻害剤市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

An oncogene inhibitor is a type of therapeutic agent or drug developed to inhibit the function of oncogenes, which are genes capable of triggering cancer when they become overactive or mutated. These inhibitors specifically target the abnormal proteins that oncogenes produce, which are responsible for driving unregulated cell division and tumor growth. By impeding these proteins, oncogene inhibitors can help to reduce or halt the development of certain cancers.

Oncogene inhibitors are mainly available in two forms: oral and injectable. Oral medications are taken by mouth and typically come in forms such as pills, tablets, capsules, or liquid solutions. These are used across various drug categories, including biologics, small molecule drugs, and combination therapies. The key indications include breast cancer, ovarian cancer, lung cancer, pancreatic cancer, and others. These drugs are distributed through several channels, including hospital pharmacies, retail pharmacies, and online pharmacies, and they are utilized by different end users such as hospitals, specialty clinics, and other healthcare facilities.

The oncogene inhibitor market research report is one of a series of new reports from The Business Research Company that provides oncogene inhibitor market statistics, including oncogene inhibitor industry global market size, regional shares, competitors with an oncogene inhibitor market share, oncogene inhibitor market segments, market trends and opportunities, and any further data you may need to thrive in the oncogene inhibitor industry. This oncogene inhibitor market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The oncogene inhibitor market size has grown strongly in recent years. It will grow from $39.68 billion in 2024 to $43.27 billion in 2025 at a compound annual growth rate (CAGR) of 9.0%. The growth in the historic period is due to factors such as increased research on resistance mechanisms, the expansion of targeted therapies, heightened research efforts for lung cancer treatment, rising investment in KRAS and MYC inhibitors, and boosted funding and grants.

The oncogene inhibitor market size is expected to see strong growth in the next few years. It will grow to $60.36 billion in 2029 at a compound annual growth rate (CAGR) of 8.7%. The growth in the forecast period is due to increased healthcare investments, the emphasis on tumor-agnostic treatments, rising use of targeted therapies, supportive regulatory and reimbursement frameworks, and the advancement of personalized medicine and companion diagnostics. Key trends expected during this period include the emergence of next-generation KRAS inhibitors, AI-powered drug discovery platforms, integration of real-time liquid biopsy, modulation of the tumor microenvironment, and the development of targeted nanoparticle-based drug delivery systems.

An increase in the prevalence of cancer is expected to propel the growth of the oncogene inhibitor market going forward. Cancer refers to a group of diseases characterized by the uncontrolled growth and spread of abnormal cells in the body. It is increasing due to unhealthy lifestyles, as habits such as smoking, poor diet, lack of exercise, and alcohol use weaken the body and promote the growth of cancerous cells. Oncogene inhibitors help combat cancer by targeting and blocking specific genes that drive cancer cell growth, thereby slowing or stopping tumor development and progression. For instance, in July 2024, according to a report published by Cancer Research UK, a UK-based charity, the average annual number of new melanoma skin cancer cases in the UK is expected to increase from approximately 20,800 in 2023-2025 to around 26,500 in 2038-2040. Therefore, an increase in the prevalence of cancer is driving the growth of the oncogene inhibitor market.

Major companies operating in the oncogene inhibitor market are focusing on developing innovative treatment options, such as novel functional genomic approaches, to enhance the precision and efficacy of cancer treatments. Novel functional genomic approaches refer to advanced methodologies that integrate various genomic, transcriptomic, and epigenomic data to understand gene functions and their roles in diseases such as cancer. For instance, in May 2024, Delphia Therapeutics, a US-based biotechnology company, introduced a novel approach called activation lethality to exploit cancer's vulnerability to oncogene overactivation. Leading oncology drug developers Kevin Marks, Bill Sellers, and Mike Dillon have secured $67 million in funding to advance this strategy. Activation lethality targets the excessive activation of oncogenes, genes that, when mutated or highly expressed, can drive cancer development. Some cancer cells rely on this overactivation for survival, and by inducing lethal stress through targeted intervention, this approach selectively kills those cancer cells while sparing healthy ones.

In November 2023, Revolution Medicines Inc., a US-based biotech company, acquired EQRx for an undisclosed amount. Through this acquisition, EQRx benefits by aligning with a company that has a strong focus on developing RAS(ON) inhibitor drugs for RAS-driven cancers, potentially accelerating the development and commercialization of its oncology programs. Additionally, the acquisition offers EQRx greater access to resources, expertise, and infrastructure, enhancing its ability to advance innovative oncogene inhibitor therapies. EQRx Inc. is a US-based biotech company that offers oncogene inhibitors.

Major players in the oncogene inhibitor market are Pfizer Inc., Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd, Merck & Co. Inc., AbbVie Inc., Bayer AG, Bristol-Myers Squibb Company, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Mirati Therapeutics Inc., AstraZeneca PLC, Incyte Corporation, Blueprint Medicines Corporation, Astex Pharmaceuticals Inc., G1 Therapeutics Inc., Nurix Therapeutics Inc., GenFleet Therapeutics Co Ltd., Relay Therapeutics Inc.

North America was the largest region in the oncogene inhibitor market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in oncogene inhibitor report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the oncogene inhibitor market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The oncogene inhibitor market consists of sales of imatinib, erlotinib, gefitinib, vemurafenib, dabrafenib, crizotinib, and ceritinib. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Oncogene Inhibitor Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on oncogene inhibitor market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for oncogene inhibitor ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The oncogene inhibitor market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Oral; Injection
• 2) By Drug Class: Small Molecule Drugs; Biologics; Combination Therapies
• 3) By Indication: Breast Cancer; Ovarian Cancer; Lung Cancer; Pancreas Cancer; Other Indications
• 4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
• 5) By End-Users: Hospitals; Specialty Clinics; Other End-Users
• Subsegments:
• 1) By Oral Oncogene Inhibitors: Small Molecule Inhibitors; Targeted Therapy Pills; Tyrosine Kinase Inhibitors (TKIs)
• 2) By Injection Oncogene Inhibitors: Monoclonal Antibodies (mAbs); Peptide Receptor Radioligand Therapy (PRRT); Small Molecule Inhibitors (Injectable); Gene Therapy Injections
• Companies Mentioned: Pfizer Inc.; Johnson & Johnson Services Inc.; F. Hoffmann-La Roche Ltd; Merck & Co. Inc.; AbbVie Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Oncogene Inhibitor Market Characteristics

3. Oncogene Inhibitor Market Trends And Strategies

4. Oncogene Inhibitor Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Oncogene Inhibitor Growth Analysis And Strategic Analysis Framework

• 5.1. Global Oncogene Inhibitor PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Oncogene Inhibitor Market Growth Rate Analysis
• 5.4. Global Oncogene Inhibitor Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Oncogene Inhibitor Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Oncogene Inhibitor Total Addressable Market (TAM)

6. Oncogene Inhibitor Market Segmentation

• 6.1. Global Oncogene Inhibitor Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Injection
• 6.2. Global Oncogene Inhibitor Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Small Molecule Drugs
• Biologics
• Combination Therapies
• 6.3. Global Oncogene Inhibitor Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Breast Cancer
• Ovarian Cancer
• Lung Cancer
• Pancreas Cancer
• Other Indications
• 6.4. Global Oncogene Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• 6.5. Global Oncogene Inhibitor Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Specialty Clinics
• Other End-Users
• 6.6. Global Oncogene Inhibitor Market, Sub-Segmentation Of Oral, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Small Molecule Inhibitors
• Targeted Therapy Pills
• Tyrosine Kinase Inhibitors (TKIs)
• 6.7. Global Oncogene Inhibitor Market, Sub-Segmentation Of Injection, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Monoclonal Antibodies (MAbs)
• Peptide Receptor Radioligand Therapy (PRRT)
• Small Molecule Inhibitors (Injectable)
• Gene Therapy Injections

7. Oncogene Inhibitor Market Regional And Country Analysis

• 7.1. Global Oncogene Inhibitor Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Oncogene Inhibitor Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Oncogene Inhibitor Market

• 8.1. Asia-Pacific Oncogene Inhibitor Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Oncogene Inhibitor Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Oncogene Inhibitor Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Oncogene Inhibitor Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Oncogene Inhibitor Market

• 9.1. China Oncogene Inhibitor Market Overview
• 9.2. China Oncogene Inhibitor Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Oncogene Inhibitor Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Oncogene Inhibitor Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Oncogene Inhibitor Market

• 10.1. India Oncogene Inhibitor Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Oncogene Inhibitor Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Oncogene Inhibitor Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Oncogene Inhibitor Market

• 11.1. Japan Oncogene Inhibitor Market Overview
• 11.2. Japan Oncogene Inhibitor Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Oncogene Inhibitor Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Oncogene Inhibitor Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Oncogene Inhibitor Market

• 12.1. Australia Oncogene Inhibitor Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Oncogene Inhibitor Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Oncogene Inhibitor Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Oncogene Inhibitor Market

• 13.1. Indonesia Oncogene Inhibitor Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Oncogene Inhibitor Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Oncogene Inhibitor Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Oncogene Inhibitor Market

• 14.1. South Korea Oncogene Inhibitor Market Overview
• 14.2. South Korea Oncogene Inhibitor Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Oncogene Inhibitor Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Oncogene Inhibitor Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Oncogene Inhibitor Market

• 15.1. Western Europe Oncogene Inhibitor Market Overview
• 15.2. Western Europe Oncogene Inhibitor Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Oncogene Inhibitor Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Oncogene Inhibitor Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Oncogene Inhibitor Market

• 16.1. UK Oncogene Inhibitor Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Oncogene Inhibitor Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Oncogene Inhibitor Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Oncogene Inhibitor Market

• 17.1. Germany Oncogene Inhibitor Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Oncogene Inhibitor Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Oncogene Inhibitor Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Oncogene Inhibitor Market

• 18.1. France Oncogene Inhibitor Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Oncogene Inhibitor Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Oncogene Inhibitor Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Oncogene Inhibitor Market

• 19.1. Italy Oncogene Inhibitor Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Oncogene Inhibitor Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Oncogene Inhibitor Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Oncogene Inhibitor Market

• 20.1. Spain Oncogene Inhibitor Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Oncogene Inhibitor Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Oncogene Inhibitor Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Oncogene Inhibitor Market

• 21.1. Eastern Europe Oncogene Inhibitor Market Overview
• 21.2. Eastern Europe Oncogene Inhibitor Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Oncogene Inhibitor Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Oncogene Inhibitor Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Oncogene Inhibitor Market

• 22.1. Russia Oncogene Inhibitor Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Oncogene Inhibitor Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Oncogene Inhibitor Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Oncogene Inhibitor Market

• 23.1. North America Oncogene Inhibitor Market Overview
• 23.2. North America Oncogene Inhibitor Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Oncogene Inhibitor Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Oncogene Inhibitor Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Oncogene Inhibitor Market

• 24.1. USA Oncogene Inhibitor Market Overview
• 24.2. USA Oncogene Inhibitor Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Oncogene Inhibitor Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Oncogene Inhibitor Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Oncogene Inhibitor Market

• 25.1. Canada Oncogene Inhibitor Market Overview
• 25.2. Canada Oncogene Inhibitor Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Oncogene Inhibitor Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Oncogene Inhibitor Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Oncogene Inhibitor Market

• 26.1. South America Oncogene Inhibitor Market Overview
• 26.2. South America Oncogene Inhibitor Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Oncogene Inhibitor Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Oncogene Inhibitor Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Oncogene Inhibitor Market

• 27.1. Brazil Oncogene Inhibitor Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Oncogene Inhibitor Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Oncogene Inhibitor Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Oncogene Inhibitor Market

• 28.1. Middle East Oncogene Inhibitor Market Overview
• 28.2. Middle East Oncogene Inhibitor Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Oncogene Inhibitor Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Oncogene Inhibitor Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Oncogene Inhibitor Market

• 29.1. Africa Oncogene Inhibitor Market Overview
• 29.2. Africa Oncogene Inhibitor Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Oncogene Inhibitor Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Oncogene Inhibitor Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Oncogene Inhibitor Market Competitive Landscape And Company Profiles

• 30.1. Oncogene Inhibitor Market Competitive Landscape
• 30.2. Oncogene Inhibitor Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Johnson & Johnson Services Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. F. Hoffmann-La Roche Ltd Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Oncogene Inhibitor Market Other Major And Innovative Companies

• 31.1. Bayer AG
• 31.2. Bristol-Myers Squibb Company
• 31.3. Novartis AG
• 31.4. GlaxoSmithKline plc
• 31.5. Takeda Pharmaceutical Company Limited
• 31.6. Eli Lilly and Company
• 31.7. Mirati Therapeutics Inc.
• 31.8. AstraZeneca PLC
• 31.9. Incyte Corporation
• 31.10. Blueprint Medicines Corporation
• 31.11. Astex Pharmaceuticals Inc.
• 31.12. G1 Therapeutics Inc.
• 31.13. Nurix Therapeutics Inc.
• 31.14. GenFleet Therapeutics Co Ltd.
• 31.15. Relay Therapeutics Inc.

32. Global Oncogene Inhibitor Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Oncogene Inhibitor Market

34. Recent Developments In The Oncogene Inhibitor Market

35. Oncogene Inhibitor Market High Potential Countries, Segments and Strategies

• 35.1 Oncogene Inhibitor Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Oncogene Inhibitor Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Oncogene Inhibitor Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer